SSRIs, rather than SNRIs, may benefit patients with true bipolar II disorder because the bell‐shaped dose–response relationship may lead to inhibition of manic/hypomanic switches with dose escalation via 5‐HT1A autoreceptor activation without noradrenaline activation. The gene discussed is HTR1A; the disease is bipolar II disorder.